Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1084 triplet versus standard first-line therapy in KRAS G12C-mutant advanced colorectal cancer
NL-OMON59067Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of calderasib, cetuximab, fluorouracil, oxaliplatin, folinic acid and 1 more in colorectal cancer (CRC) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of participants experiencing dose-limiting toxicity, Number of participants who experience an adverse event and 2 more. Started Oct 2025; status: recruiting.
02
Drugs
calderasibcetuximabfluorouraciloxaliplatinfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON59067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59067.